Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.96EUR
18 May 2018
Change (% chg)

€0.00 (+0.17%)
Prev Close
€2.96
Open
€3.00
Day's High
€3.02
Day's Low
€2.94
Volume
27,744
Avg. Vol
98,876
52-wk High
€3.79
52-wk Low
€2.40

Select another date:

Thu, Apr 26 2018

BRIEF-Transgene Q1 Operating Revenue Stable At 1.8 Million Euros

* TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018

BRIEF-Transgene Says PCPV Most Promising Therapeutic Candidate Amongst Evaluated Poxviridae

* PCPV WAS FOUND TO BE MOST PROMISING THERAPEUTIC CANDIDATE AMONGST POXVIRIDAE EVALUATED BY TRANSGENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene To Announce Major Clinical Results In 2018

* TRANSGENE TO ANNOUNCE MAJOR CLINICAL RESULTS IN 2018 AND ACHIEVE PROMISING PROGRESS ON ITS NEW ONCOLYTIC VIRUSES

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

* ‍FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101​

BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​

* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

Select another date: